Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial

Background. Elderly persons often experience a reduced immune response to influenza vaccination. We evaluated the usual dose of AS03A-adjuvanted H5N1 pandemic vaccine (3.75 μg hemagglutinin of A/Vietnam/1194/2004-like strain) compared with a double dose in an elderly population.

Bibliographic Details
Main Authors: Heijmans, Stéphane, De Meulemeester, Marc, Reynders, Paul, Giet, Didier, Demanet, Etienne, Devresse, Pierre-Yves, Icardi, Giancarlo, Dramé, Mamadou, Roman, François, Gillard, Paul
Format: Online
Language:English
Published: Oxford University Press 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068020/
id pubmed-3068020
recordtype oai_dc
spelling pubmed-30680202012-04-15 Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial Heijmans, Stéphane De Meulemeester, Marc Reynders, Paul Giet, Didier Demanet, Etienne Devresse, Pierre-Yves Icardi, Giancarlo Dramé, Mamadou Roman, François Gillard, Paul Major Articles and Brief Reports Background. Elderly persons often experience a reduced immune response to influenza vaccination. We evaluated the usual dose of AS03A-adjuvanted H5N1 pandemic vaccine (3.75 μg hemagglutinin of A/Vietnam/1194/2004-like strain) compared with a double dose in an elderly population. Oxford University Press 2011-04-15 /pmc/articles/PMC3068020/ /pubmed/21450995 http://dx.doi.org/10.1093/infdis/jiq174 Text en © The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Heijmans, Stéphane
De Meulemeester, Marc
Reynders, Paul
Giet, Didier
Demanet, Etienne
Devresse, Pierre-Yves
Icardi, Giancarlo
Dramé, Mamadou
Roman, François
Gillard, Paul
spellingShingle Heijmans, Stéphane
De Meulemeester, Marc
Reynders, Paul
Giet, Didier
Demanet, Etienne
Devresse, Pierre-Yves
Icardi, Giancarlo
Dramé, Mamadou
Roman, François
Gillard, Paul
Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
author_facet Heijmans, Stéphane
De Meulemeester, Marc
Reynders, Paul
Giet, Didier
Demanet, Etienne
Devresse, Pierre-Yves
Icardi, Giancarlo
Dramé, Mamadou
Roman, François
Gillard, Paul
author_sort Heijmans, Stéphane
title Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
title_short Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
title_full Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
title_fullStr Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
title_full_unstemmed Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
title_sort immunogenicity profile of a 3.75-μg hemagglutinin pandemic rh5n1 split virion as03a-adjuvanted vaccine in elderly persons: a randomized trial
description Background. Elderly persons often experience a reduced immune response to influenza vaccination. We evaluated the usual dose of AS03A-adjuvanted H5N1 pandemic vaccine (3.75 μg hemagglutinin of A/Vietnam/1194/2004-like strain) compared with a double dose in an elderly population.
publisher Oxford University Press
publishDate 2011
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068020/
_version_ 1611447722005495808

Similar Items